| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2008 ( Subtotal = $148,503 ) |
| | 2008 | 2008 | LENTIGEN CORPORATION | 1450 SOUTH ROLLING ROAD | BALTIMORE | MD | 21227 | BALTIMORE | USA | R41CA130547 | LENTIVIRAL REDIRECTED T CELLS FOR B CANCER IMMUNOTHERAPY | 000 | 2 | NIH | 8/20/2008 | $148,503 |
|
| Issue Date FY: 2007 ( Subtotal = $707,511 ) |
| | 2007 | 2007 | LENTIGEN CORPORATION | 1450 SOUTH ROLLING ROAD | BALTIMORE | MD | 21227 | BALTIMORE | USA | R41CA130547 | LENTIVIRAL REDIRECTED T CELLS FOR B CANCER IMMUNOTHERAPY | 000 | 1 | NIH | 9/28/2007 | $283,753 |
| | 2007 | 2007 | LENTIGEN CORPORATION | 1450 SOUTH ROLLING ROAD | BALTIMORE | MD | 21227 | BALTIMORE | USA | R43CA130294 | T CELL RECEPTOR GENE VECTORS FOR EBV DISEASE | 000 | 1 | NIH | 8/31/2007 | $134,081 |
| | 2007 | 2007 | LENTIGEN CORPORATION | 1450 SOUTH ROLLING ROAD | BALTIMORE | MD | 21227 | BALTIMORE | USA | R43AI073097 | LENTIVIRAL VECTORS FOR TCR IMMUNOTHERAPY TARGETED TO HCV | 000 | 1 | NIH | 4/6/2007 | $289,677 |
|
| Issue Date FY: 2006 ( Subtotal = $594,236 ) |
| | 2006 | 2006 | LENTIGEN CORPORATION | 1450 SOUTH ROLLING ROAD | BALTIMORE | MD | 21227 | BALTIMORE | USA | R43CA124274 | IMMUNOTHERAPY OF CLL WITH LENTIVIRAL EXPRESSED CD40-LIGAND | 000 | 1 | NIH | 9/12/2006 | $114,645 |
| | 2006 | 2006 | LENTIGEN CORPORATION | 1450 SOUTH ROLLING ROAD | BALTIMORE | MD | 21227 | BALTIMORE | USA | R43CA126461 | LENTIVIRAL VECTORS FOR TCR IMMUNOTHERAPY TARGETED TO MELANOMA | 000 | 1 | NIH | 9/28/2006 | $243,003 |
| | 2006 | 2006 | LENTIGEN CORPORATION | 1450 SOUTH ROLLING ROAD | BALTIMORE | MD | 21227 | BALTIMORE | USA | R43CA124273 | LENTIVIRAL ENGINEERED T CELL IMMUNOTHERAPY IN TUMORS OVEREXPRESSING MESOTHELIN | 000 | 1 | NIH | 8/31/2006 | $236,588 |
|
|
